周文杰;吴洁;
ZHOU Wen-jie;WU Jie;Department of Obstetrics and Gynecology, the First Affiliated Hospital of Nanjing Medical University,Jiangsu Province Hospital;

• 1:江苏省人民医院/南京医科大学第一附属医院妇产科

摘要(Abstract)：

医学的快速发展显著提高了恶性肿瘤患者的生存率和生存时间,因此,越来越多的女性恶性肿瘤幸存者将经历自然绝经或由于肿瘤治疗导致的早发性卵巢功能不全(premature ovarian insufficiency, POI)。自然绝经或POI带来的雌激素水平缺乏,可引起潮热、出汗、失眠、泌尿生殖道萎缩等一系列症状,远期负面影响包括心血管疾病、骨质疏松等风险增加,严重影响女性生活质量。因此,绝经激素治疗(menopausal hormone therapy, MHT)在女性恶性肿瘤幸存者中的应用日益受到关注。本文将对MHT与女性恶性肿瘤的关系及恶性肿瘤幸存者应用MHT的利弊进行分析。
The rapid development of medicine has improved the survival rate and survival time of women with malignant tumors. More and more women with malignant tumors are experiencing either natural menopause or premature ovarian insufficiency(POI) due to the side effects of tumor therapy. Estrogen deficiency causes a series of perimenopausal symptoms such as hot flashes, sweating, insomnia, and urogenital tract atrophy, as well as long-term negative risks of cardiovascular disease and osteoporosis, which seriously affect women's quality of life. Therefore, the application of menopausal hormone therapy(MHT) in female malignant tumor survivors was increasingly concerned. Therefore, we evaluated the benefits and risks of MHT in female malignant tumor survivors in this review.

关键词(KeyWords)： 女性;恶性肿瘤;绝经激素治疗;获益;风险
female;malignant tumor;menopausal hormone therapy;benefit;risk

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金面上项目(81771540);; 江苏省妇幼保健重点学科(FXK201701);; 江苏省医学创新团队(CXTDA2017004)~~

作者(Authors): 周文杰;吴洁;
ZHOU Wen-jie;WU Jie;Department of Obstetrics and Gynecology, the First Affiliated Hospital of Nanjing Medical University,Jiangsu Province Hospital;

参考文献(References)：

• [1] 中华医学会妇产科学分会绝经学组.中国绝经管理与绝经激素治疗指南(2018)[J].协和医学杂志，2018,9:512- 525.[1] Menopause Group,Obstertrics and Gynecology Branch,Chinese Medical Association.2018 Chinese Guideline on Menopause Management and Menopause Hormone Therapy[J].Xie He Yi Xue Za Zhi,2018,9:512- 525.
• [2] 中华医学会妇产科学分会绝经学组.早发性卵巢功能不全的激素补充治疗专家共识[J].中华妇产科杂志，2016,51:881- 886[2] Menopause Group,Obstertrics and Gynecology Branch,Chinese Medical Association.2016 Consensus of hormone replacement therapy for premature ovarian insufficiency[J].Zhonghua Fu Chan Ke Za Zhi,2016,51:881- 886.
• [3] Rossouw JE,Anderson GL,Prentice RL,et al.Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results from the Women's Health Initiative randomized controlled trial[J].JAMA,2002,288:321- 333.
• [4] Chlebowski RT,Rohan TE,Manson JE,et al.Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone:Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials[J].JAMA Oncol,2015,1:296- 305.
• [5] Crandall CJ,Hovey KM,Andrews C,et al.Comparison of clinical outcomes among users of oral and transdermal estrogen therapy in the Women' s Health Initiative Observational Study[J].Menopause,2017,24:1145- 1153.
• [6] Chlebowski RT,Hendrix SL,Langer RD,et al.Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women:the Women's Health Initiative randomized trial[J].JAMA,2003,289:3243- 3253.
• [7] Stahlberg C,Pedersen AT,Andersen ZJ,et al.Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy[J].Br J Cancer,2004,91:644- 650.
• [8] Kotsopoulos J,Gronwald J,Karlan BY,et al.Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers[J].JAMA Oncol,2018,4:1059- 1065.
• [9] Stute P,Wildt L,Neulen J.The impact of micronized progesterone on breast cancer risk:a systematic review[J].Climacteric,2018,21:111- 122.
• [10] Fait T.Menopause hormone therapy:latest developments and clinical practice[J].Drugs Context,2019,8:212551.
• [11] Holmberg L,Anderson H.HABITS (hormonal replacement therapy after breast cancer-is it safe?),a randomised comparison:trial stopped[J].Lancet,2004,363:453- 455.
• [12] von Schoultz E,Rutqvist LE.Menopausal hormone therapy after breast cancer:The Stockholm randomized trial[J].J Natl Cancer Inst,2005,97:533- 535.
• [13] Holmberg L,Iversen OE,Rudenstam CM,et al.Increased risk of recurrence after hormone replacement therapy in breast cancer survivors[J].J Natl Cancer Inst,2008,100:475- 482.
• [14] Fahlén M,Fornander T,Johansson H,et al.Hormone replacement therapy after breast cancer:10 years follow up of the Stockholm randomised trial[J].Eur J Cancer,2013,49:52- 59.
• [15] Marsden J,Marsh M,Rigg A.British Menopause Society consensus statement on the management of estrogen deficiency symptoms,arthralgia and menopause diagnosis in women treated for early breast cancer[J].Post Reprod Health,2019,25:21- 32.
• [16] Sj?gren LL,M?rch LS,L?kkegaard E.Hormone replace-ment therapy and the risk of endometrial cancer:a systematic review[J].Maturitas,2016,91:25- 35.
• [17] Chapman JA,DiSaia PJ,Osann K,et al.Estrogen replacement in surgical stage Ⅰ and Ⅱ endometrial cancer survivors[J].Am J Obstet Gynecol,1996,175:1195- 1200.
• [18] Suriano KA,McHale M,McLaren CE,et al.Estrogen replacement therapy in endometrial cancer patients:a matched control study[J].Obstet Gynecol,2001,97:555- 560.
• [19] Barakat RR,Bundy BN,Spirtos NM,et al.Randomized double-blind trial of estrogen replacement therapy versus placebo in stage Ⅰ or Ⅱ endometrial cancer:a Gynecologic Oncology group study[J].J Clin Oncol,2006,24:587- 592.
• [20] Shim SH,Lee SJ,Kim SN.Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors:a meta-analysis Randomized double-blind trial of estrogen replacement therapy versus placebo in stage Ⅰ or Ⅱ endometrial cancer:a Gynecologic Oncology group study[J].Eur J Cancer,2014,50:1628- 1637.
• [21] Chapman JA,DiSaia PJ,Osann K,et al.Estrogen replacement in surgical stage Ⅰ and Ⅱ endometrial cancer survivors[J].Am J Obstet Gynecol,1996,175:1195- 1200.
• [22] Koh WJ,Abu-Rustum NR,Bean S,et al.Uterine Neoplasms,Version 1.2018,NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2018,16:170- 199.
• [23] Del Carmen MG,Rice LW.Management of menopausal symptoms in women with gynecologic cancers[J].Gynecol Oncol,2017,146:427- 435.
• [24] Jaakkola S,Pukkala E,K Lyytinen H,et al.Postmenopausal estradiol-progestagen therapy and risk for uterine cervical cancer[J].Int J Cancer,2012,131:E537-E543.
• [25] Ploch E.Hormonal replacement therapy in patients after cervical cancer treatment[J].Gynecol Oncol,1987,26:169- 177.
• [26] Deli T,Orosz M,Jakab A.Hormone Replacement Therapy in Cancer Survivors-Review of the Literature[J].Pathol Oncol Res,2020,26:63- 78.
• [27] Collaborative Group On Epidemiological Studies Of Ovarian Cancer,Beral V,Gaitskell K,et al.Menopausal hormone use and ovarian cancer risk:individual participant meta-analysis of 52 epidemiological studies[J].Lancet,2015,385:1835- 1842.
• [28] Manson JE,Chlebowski RT,Stefanick ML,et al.Meno-pausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials[J].JAMA,2013,310:1353- 1368.
• [29] Rasmussen ELK,Hannibal CG,Dehlendorff C,et al.Parity,infertility,oral contraceptives,and hormone replace-ment therapy and the risk of ovarianserous borderline tumors:A nationwide case-control study[J].Gynecol Oncol,2017,144:571- 576.
• [30] Guidozzi F,Daponte A.Estrogen replacement therapy for ovarian carcinoma survivors:A randomized controlled trial[J].Cancer,1999,86:1013- 1018.
• [31] Eeles RA,Morden JP,Gore M,et al.Adjuvant hormone therapy may improve survival in epithelial ovarian cancer:results of the AHT randomized trial[J].J Clin Oncol,2015,33:4138- 4144.
• [32] Pergialiotis V,Pitsouni E,Prodromidou A,et al.Hormone therapy for ovarian cancer survivors:systematic review and meta-analysis[J].Menopause,2016,23:335- 342.
• [33] Kuhle CL,Kapoor E,Sood R,et al.Menopausal hormone therapy in cancer survivors:A narrative review of the literature[J].Maturitas,2016,92:86- 96.
• [34] Biglia N,Bounous VE,Sgro LG,et al.Treatment of climacteric symptoms in survivors of gynaecological cancer[J].Maturitas,2015,82:296- 298.
• [35] Lin KJ,Cheung WY,Lai JY,et al.The effect of estrogen vs.combined estrogen-progestogen therapy on the risk of colorectal cancer[J].Int J Cancer,2012,130:419- 430.
• [36] Murphy N,Strickler HD,Stanczyk FZ,et al.A prospective evaluation of endogenous sex hormone levels and colorectal cancer risk in postmenopausal women[J].J Natl Cancer Inst,2015,107:djv210.
• [37] Caiazza F,Ryan EJ,Doherty G,et al.Estrogen receptors and their implications in colorectal carcinogenesis[J].Front Oncol,2015,5:19.
• [38] Adami HO,Persson I,Hoover R,et al.Risk of cancer in women receiving hormone replacement therapy[J].Int J Cancer,1989,44:833- 839.
• [39] Montella M,D'Arena G,Crispo A,et al.Role of Sex Hormones in the Development and Progression of Hepatitis B Virus-Associated Hepatocellular Carcinoma[J].Int J Endocrinol,2015,2015:854530.
• [40] Hassan MM,Botrus G,Abdel-Wahab R,et al.Estrogen Replacement Reduces Risk and Increases Survival Times of Women with Hepatocellular Carcinoma[J].Clin Gastroenterol Hepatol,2017,15:1791- 1799.
• [41] Hsu LH,Chu NM,Kao SH.Estrogen,Estrogen Receptor and Lung Cancer[J].Int J Mol Sci,2017,18:1713.
• [42] Chlebowski RT,Anderson GL,Manson JE,et al.Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial[J].J Natl Cancer Inst,2010,102:1413- 1421.
• [43] Ganti AK,Sahmoun AE,Panwalkar AW,et al.Hormone replacement therapy is associated with decreased survival in women with lung cancer[J].J Clin Oncol,2016,24:59- 63.
• [44] Li Q,Kopecky KJ,Mohan A,et al.Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia[J].Clin Cancer Res,1999,5:1077- 1084.
• [45] Nelson RA,Levine AM,Bernstein L.Reproductive factors and risk of intermediate-or high-grade B-cell non-Hodgkin's lymphoma in women[J].J Clin Oncol,2001,19:1381- 1387.
• [46] Medina KL,Strasser A,Kincade PW.Estrogen influences the differentiation,proliferation,and survival of early B-lineage precursors[J].Blood,2000,95:2059- 2067.
• [47] Yang X,Wang C,He X,et al.Hormone therapy for premature ovarian insufficiency patients with malignant hematologic diseases[J].Climacteric,2017,20:268- 273.
• [48] Tauchmanovà L,Selleri C,De Rosa G,et al.Estrogen-progestin therapy in women after stem cell transplant:our experience and literature review[J].Menopause,2007,14:320- 330.
• [49] Sturniolo G,Zafon C,Moleti M,et al.Immunohistochemical Expression of Estrogen Receptor-α and Progesterone Receptor in Patients with Papillary Thyroid Cancer[J].Eur Thyroid J,2016,5:224- 230.
• [50] O'Shea T,Crowley RK,Farrell M,et al.Growth of a progesterone receptor-positive meningioma in a female patient with congenital adrenal hyperplasia[J].Endocrinol Diabetes Metab Case Rep,2016,2016:16- 0054.
• [51] Pines A.Hormone therapy and brain tumors[J].Climacteric,2011,14:215- 216.
• [52] Benson VS,Kirichek O,Beral V,et al.Menopausal hormone therapy and central nervous system tumor risk:large UK prospective study and meta-analysis[J].Int J Cancer,2015,136:2369- 2377.
• [53] Shu X,Jiang Y,Wen T,et al.Association of hormone replacement therapy with increased risk of meningioma in women:A hospital-based multicenter study with propensity score matching[J].Asia Pac J Clin Oncol,2019,15:e147-e153.